Patent · US Active

Hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg

US10653772B2 · kind B2 · utility

1Cited by

0References

10Claims

0Family size

Assignee

Hemu Wang · CN

Inventors

Hemu Wang · Tianjin, CN
Changhua Wang · Sichuan, CN
Jun Yang · Beijing, CN

Key dates

Filing date	Mar 16, 2017
Grant date	May 19, 2020
Priority date	—
Expiry date	Mar 16, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12R2001/78
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula polymorpha cells. 108 cells contain 6-10 μg HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula polymorpha cells as an adjuvant.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.